image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 420.91
-0.647 %
$ 34.5 B
Market Cap
40.55
P/E
1. INTRINSIC VALUE

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits.[ Read More ]

The intrinsic value of one IDXX stock under the base case scenario is HIDDEN Compared to the current market price of 421 USD, IDEXX Laboratories, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IDXX

image
FINANCIALS
3.66 B REVENUE
8.72%
1.1 B OPERATING INCOME
22.07%
845 M NET INCOME
24.44%
907 M OPERATING CASH FLOW
66.95%
-125 M INVESTING CASH FLOW
35.88%
-442 M FINANCING CASH FLOW
-19.16%
976 M REVENUE
-2.79%
304 M OPERATING INCOME
14.45%
233 M NET INCOME
14.53%
220 M OPERATING CASH FLOW
-11.37%
-27.4 M INVESTING CASH FLOW
16.83%
-291 M FINANCING CASH FLOW
-38.40%
Balance Sheet Decomposition IDEXX Laboratories, Inc.
image
Current Assets 1.5 B
Cash & Short-Term Investments 454 M
Receivables 530 M
Other Current Assets 512 M
Non-Current Assets 1.76 B
Long-Term Investments 56.2 M
PP&E 818 M
Other Non-Current Assets 891 M
Current Liabilities 952 M
Accounts Payable 111 M
Short-Term Debt 345 M
Other Current Liabilities 496 M
Non-Current Liabilities 824 M
Long-Term Debt 723 M
Other Non-Current Liabilities 101 M
EFFICIENCY
Earnings Waterfall IDEXX Laboratories, Inc.
image
Revenue 3.66 B
Cost Of Revenue 1.47 B
Gross Profit 2.19 B
Operating Expenses 1.09 B
Operating Income 1.1 B
Other Expenses 252 M
Net Income 845 M
RATIOS
59.82% GROSS MARGIN
59.82%
29.97% OPERATING MARGIN
29.97%
23.08% NET MARGIN
23.08%
56.92% ROE
56.92%
25.92% ROA
25.92%
35.92% ROIC
35.92%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IDEXX Laboratories, Inc.
image
Net Income 845 M
Depreciation & Amortization 115 M
Capital Expenditures -134 M
Stock-Based Compensation 59.7 M
Change in Working Capital -72.4 M
Others 18.2 M
Free Cash Flow 773 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IDEXX Laboratories, Inc.
image
Wall Street analysts predict an average 1-year price target for IDXX of $501 , with forecasts ranging from a low of $247 to a high of $600 .
IDXX Lowest Price Target Wall Street Target
247 USD -41.32%
IDXX Average Price Target Wall Street Target
501 USD 19.07%
IDXX Highest Price Target Wall Street Target
600 USD 42.55%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership IDEXX Laboratories, Inc.
image
Sold
0-3 MONTHS
235 K USD 1
3-6 MONTHS
108 K USD 1
6-9 MONTHS
5.32 M USD 2
9-12 MONTHS
34.6 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 06, 2024
Sell 235 K USD
SZOSTAK M ANNE
Director
- 500
469.3723 USD
6 months ago
May 17, 2024
Sell 108 K USD
Claflin Bruce L.
Director
- 200
540.8 USD
8 months ago
Mar 06, 2024
Sell 2.31 M USD
POLEWACZYK JAMES F
Executive Vice President
- 4134
557.941 USD
8 months ago
Mar 06, 2024
Sell 1.84 M USD
POLEWACZYK JAMES F
Executive Vice President
- 3290
558.8822 USD
8 months ago
Mar 06, 2024
Sell 380 K USD
POLEWACZYK JAMES F
Executive Vice President
- 680
559.3318 USD
8 months ago
Mar 05, 2024
Sell 790 K USD
Vandebroek Sophie V.
Director
- 1404
562.9822 USD
9 months ago
Feb 08, 2024
Sell 692 K USD
FENNELL GEORGE
SVP, Chief Revenue Officer
- 1209
572.1356 USD
9 months ago
Feb 08, 2024
Sell 1.31 M USD
FENNELL GEORGE
SVP, Chief Revenue Officer
- 2279
572.7797 USD
9 months ago
Feb 08, 2024
Sell 646 K USD
FENNELL GEORGE
SVP, Chief Revenue Officer
- 1125
573.9761 USD
9 months ago
Feb 08, 2024
Sell 1.82 M USD
FENNELL GEORGE
SVP, Chief Revenue Officer
- 3173
575.0167 USD
9 months ago
Feb 08, 2024
Sell 237 K USD
FENNELL GEORGE
SVP, Chief Revenue Officer
- 412
575.8027 USD
9 months ago
Feb 07, 2024
Sell 347 K USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 615
563.8158 USD
9 months ago
Feb 07, 2024
Sell 893 K USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 1581
564.976 USD
9 months ago
Feb 07, 2024
Sell 397 K USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 701
566.533 USD
9 months ago
Feb 07, 2024
Sell 887 K USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 1564
567.3487 USD
9 months ago
Feb 07, 2024
Sell 836 K USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 1469
568.8449 USD
9 months ago
Feb 07, 2024
Sell 2.23 M USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 3912
569.9132 USD
9 months ago
Feb 07, 2024
Sell 3.24 M USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 5675
570.9697 USD
9 months ago
Feb 07, 2024
Sell 4.08 M USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 7128
571.8381 USD
9 months ago
Feb 07, 2024
Sell 390 K USD
MCKEON BRIAN P
EVP, CFO and Treasurer
- 681
572.8041 USD
9 months ago
Feb 07, 2024
Sell 3.06 M USD
MAZELSKY JONATHAN JAY
President and CEO
- 5356
571.7066 USD
9 months ago
Feb 07, 2024
Sell 2.36 M USD
MAZELSKY JONATHAN JAY
President and CEO
- 4124
572.5253 USD
9 months ago
Feb 07, 2024
Sell 265 K USD
MAZELSKY JONATHAN JAY
President and CEO
- 462
573.1911 USD
9 months ago
Feb 07, 2024
Sell 778 K USD
MAZELSKY JONATHAN JAY
President and CEO
- 1353
574.7515 USD
9 months ago
Feb 07, 2024
Sell 406 K USD
MAZELSKY JONATHAN JAY
President and CEO
- 705
575.4769 USD
11 months ago
Dec 07, 2023
Sell 1.62 M USD
POLEWACZYK JAMES F
Executive Vice President
- 3116
520.1922 USD
11 months ago
Dec 07, 2023
Sell 1.76 M USD
POLEWACZYK JAMES F
Executive Vice President
- 3378
521.0046 USD
11 months ago
Dec 07, 2023
Sell 628 K USD
POLEWACZYK JAMES F
Executive Vice President
- 1202
522.3094 USD
11 months ago
Dec 07, 2023
Sell 2.06 M USD
POLEWACZYK JAMES F
Executive Vice President
- 3940
523.5563 USD
11 months ago
Dec 04, 2023
Sell 2.98 M USD
MAZELSKY JONATHAN JAY
President and CEO
- 5804
512.95 USD
11 months ago
Dec 04, 2023
Sell 680 K USD
MAZELSKY JONATHAN JAY
President and CEO
- 1324
513.51 USD
1 year ago
Aug 31, 2023
Sell 6.87 M USD
MAZELSKY JONATHAN JAY
President and CEO
- 13424
512.0133 USD
1 year ago
Aug 29, 2023
Sell 254 K USD
POLEWACZYK JAMES F
Executive Vice President
- 500
508.9642 USD
1 year ago
Aug 29, 2023
Sell 1.3 M USD
POLEWACZYK JAMES F
Executive Vice President
- 2545
509.3207 USD
1 year ago
Aug 29, 2023
Sell 3.16 M USD
POLEWACZYK JAMES F
Executive Vice President
- 6186
510.3776 USD
1 year ago
Aug 29, 2023
Sell 1.69 M USD
POLEWACZYK JAMES F
Executive Vice President
- 3318
510.4664 USD
1 year ago
Aug 29, 2023
Sell 3.82 M USD
POLEWACZYK JAMES F
Executive Vice President
- 7473
511.0286 USD
1 year ago
Aug 29, 2023
Sell 1.48 M USD
POLEWACZYK JAMES F
Executive Vice President
- 2887
511.2237 USD
1 year ago
Aug 15, 2023
Sell 0 USD
AYERS JONATHAN W
Director
- 492
0 USD
1 year ago
Aug 03, 2023
Sell 8.17 M USD
Lane Michael
Executive Vice President
- 16027
510 USD
1 year ago
May 18, 2023
Sell 486 K USD
AYERS JONATHAN W
Director
- 1000
486.482 USD
1 year ago
May 19, 2023
Sell 554 K USD
AYERS JONATHAN W
Director
- 1138
486.9211 USD
1 year ago
May 19, 2023
Sell 1.1 M USD
AYERS JONATHAN W
Director
- 2254
487.8169 USD
1 year ago
May 18, 2023
Sell 1.34 M USD
AYERS JONATHAN W
Director
- 2753
487.8353 USD
1 year ago
May 19, 2023
Sell 639 K USD
AYERS JONATHAN W
Director
- 1308
488.7748 USD
1 year ago
May 18, 2023
Sell 494 K USD
AYERS JONATHAN W
Director
- 1012
488.6343 USD
1 year ago
May 19, 2023
Sell 147 K USD
AYERS JONATHAN W
Director
- 300
490.0283 USD
1 year ago
May 19, 2023
Sell 197 K USD
AYERS JONATHAN W
Director
- 400
491.59 USD
1 year ago
May 19, 2023
Sell 703 K USD
AYERS JONATHAN W
Director
- 1426
492.8167 USD
1 year ago
May 18, 2023
Sell 1.1 M USD
AYERS JONATHAN W
Director
- 2242
489.7081 USD
1 year ago
May 19, 2023
Sell 607 K USD
AYERS JONATHAN W
Director
- 1229
494.276 USD
1 year ago
May 18, 2023
Sell 832 K USD
AYERS JONATHAN W
Director
- 1695
490.7719 USD
1 year ago
May 19, 2023
Sell 439 K USD
AYERS JONATHAN W
Director
- 886
495.9351 USD
1 year ago
May 19, 2023
Sell 378 K USD
AYERS JONATHAN W
Director
- 759
497.6556 USD
1 year ago
May 18, 2023
Sell 638 K USD
AYERS JONATHAN W
Director
- 1298
491.9058 USD
1 year ago
May 19, 2023
Sell 150 K USD
AYERS JONATHAN W
Director
- 300
498.48 USD
1 year ago
May 05, 2023
Sell 332 K USD
SZOSTAK M ANNE
Director
- 700
473.59 USD
1 year ago
May 05, 2023
Sell 380 K USD
SZOSTAK M ANNE
Director
- 800
475.27 USD
1 year ago
May 05, 2023
Sell 238 K USD
SZOSTAK M ANNE
Director
- 500
476.12 USD
1 year ago
May 05, 2023
Sell 484 K USD
Lane Michael
Executive Vice President
- 1000
484 USD
1 year ago
May 04, 2023
Sell 1.03 M USD
Vandebroek Sophie V.
Director
- 2187
469.0169 USD
1 year ago
Feb 16, 2023
Sell 1.12 M USD
JUNIUS DANIEL M
Director
- 2187
511.6797 USD
1 year ago
Feb 15, 2023
Sell 510 K USD
Turner Kathy V
Senior Vice President
- 1000
510.0312 USD
1 year ago
Feb 16, 2023
Sell 5.16 K USD
Turner Kathy V
Senior Vice President
- 10
515.575 USD
1 year ago
Feb 14, 2023
Sell 505 K USD
Turner Kathy V
Senior Vice President
- 1000
505.059 USD
1 year ago
Feb 14, 2023
Sell 158 K USD
Turner Kathy V
Senior Vice President
- 313
504.6616 USD
1 year ago
Feb 14, 2023
Sell 291 K USD
Turner Kathy V
Senior Vice President
- 577
504.0923 USD
1 year ago
Feb 14, 2023
Sell 55.3 K USD
Turner Kathy V
Senior Vice President
- 110
502.814 USD
1 year ago
Feb 09, 2023
Sell 505 K USD
Turner Kathy V
Senior Vice President
- 1000
505.0374 USD
1 year ago
Dec 05, 2022
Sell 1.29 M USD
JUNIUS DANIEL M
Director
- 3046
424.91 USD
1 year ago
Dec 02, 2022
Sell 317 K USD
SZOSTAK M ANNE
Director
- 740
428.55 USD
1 year ago
Dec 01, 2022
Sell 1.31 M USD
Turner Kathy V
Senior Vice President
- 3000
436 USD
2 years ago
Nov 14, 2022
Sell 421 K USD
MAZELSKY JONATHAN JAY
President & CEO
- 972
433.3741 USD
2 years ago
Nov 14, 2022
Sell 2.77 M USD
MAZELSKY JONATHAN JAY
President & CEO
- 6385
434.2615 USD
2 years ago
Nov 14, 2022
Sell 1.11 M USD
MAZELSKY JONATHAN JAY
President & CEO
- 2543
435.0712 USD
2 years ago
Nov 14, 2022
Sell 262 K USD
MAZELSKY JONATHAN JAY
President & CEO
- 600
435.8775 USD
2 years ago
Nov 11, 2022
Sell 1.13 M USD
Turner Kathy V
Senior Vice President
- 2567
442.0468 USD
2 years ago
Nov 11, 2022
Sell 1.31 M USD
Turner Kathy V
Senior Vice President
- 3000
438 USD
2 years ago
Nov 10, 2022
Sell 1.09 M USD
Turner Kathy V
Senior Vice President
- 2655
410.0175 USD
2 years ago
Nov 10, 2022
Sell 10.2 K USD
Turner Kathy V
Senior Vice President
- 25
406.112 USD
2 years ago
Nov 11, 2022
Sell 1.31 M USD
Turner Kathy V
Senior Vice President
- 3000
436.0623 USD
2 years ago
Nov 07, 2022
Sell 341 K USD
MAZELSKY JONATHAN JAY
President & CEO
- 900
378.5951 USD
2 years ago
Nov 07, 2022
Sell 759 K USD
MAZELSKY JONATHAN JAY
President & CEO
- 2000
379.4994 USD
2 years ago
Nov 07, 2022
Sell 190 K USD
MAZELSKY JONATHAN JAY
President & CEO
- 500
380.852 USD
2 years ago
Nov 07, 2022
Sell 1.42 M USD
MAZELSKY JONATHAN JAY
President & CEO
- 3704
382.8057 USD
2 years ago
Nov 07, 2022
Sell 1.04 M USD
MAZELSKY JONATHAN JAY
President & CEO
- 2716
383.2864 USD
2 years ago
Nov 07, 2022
Sell 1.16 M USD
MAZELSKY JONATHAN JAY
President & CEO
- 3018
384.4651 USD
2 years ago
Nov 07, 2022
Sell 151 K USD
MAZELSKY JONATHAN JAY
President & CEO
- 392
385.0122 USD
7. News
IDEXX Laboratories Q3: Weak End-Market Demand Continues I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. seekingalpha.com - 6 days ago
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. fool.com - 1 week ago
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today. fool.com - 1 week ago
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com - 2 weeks ago
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points inclu. businesswire.com - 2 weeks ago
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68. benzinga.com - 2 weeks ago
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments. zacks.com - 2 weeks ago
Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 weeks ago
Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago. zacks.com - 2 weeks ago
IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners. reuters.com - 2 weeks ago
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company reports revenues of $976 million for the third quarter of 2024, an increase of 7% as reported and 6% organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and 6% organic, and Water revenue growth of 13% as reported and organic. CAG Diagnostics recurring revenue growth of 7% as repor. businesswire.com - 2 weeks ago
Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 weeks ago
8. Profile Summary

IDEXX Laboratories, Inc. IDXX

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 34.5 B
Dividend Yield 0.00%
Description IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Contact One IDEXX Drive, Westbrook, ME, 04092 https://www.idexx.com
IPO Date June 21, 1991
Employees 11000
Officers Mr. Brian P. McKeon Chief Financial Officer, Executive Vice President & Treasurer Mr. Michael Erickson Ph.D. Executive Vice President and GM of Point of Care Diagnostics & Telemedicine Mr. Ken Grady Senior Vice President & Chief Information Officer Mr. John Hart Senior Vice President of Global Operations Mr. Michael J. Lane Executive Vice President and GM of Reference Laboratories & Information Technology Dr. Martin Smith Ph.D. Executive Vice President & Chief Technology Officer Mr. Jonathan J. Mazelsky President, Chief Executive Officer & Director Mr. Jeffery D. Chadbourne Senior Vice President of Commercial Finance & Sales Operations Mr. Michael P. Johnson Executive Vice President & Chief Human Resources Officer Mr. George J. Fennell Senior Vice President & Chief Revenue Officer